List view / Grid view
New study finds patients receiving chemotherapy have lower COVID-19 antibody levels post-vaccination than patients receiving targeted cancer therapy.
BioNTech expands clinical oncology portfolio with first patient dosed in Phase II trial of mRNA-based vaccine for colorectal cancer.
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.
Trodelvy significantly improved overall survival and demonstrated clinically meaningful improvements in quality of life in Phase III study.
Opdivo and Yervoy displayed a 23 percent survival rate at three years compared to 15 percent with chemotherapy, Phase III trial shows.
US FDA have accepted Biologics License Application (BLA) for tislelizumab for the treatment of oesophageal squamous cell carcinoma cancer.
David Vincent, Process Development Lead at eXmoor Pharma, details some of the critical steps that form the manufacturing strategy for providers of cell and gene therapies.
Pfizer will acquire Trillium Therapeutics, an immuno-oncology company, potentially enhancing growth of cancer treatments from 2026.
The European Commission (EC) has approved Abecma, the first anti-BCMA CAR T-cell therapy for patients with multiple myeloma.
BioNTech acquires Kite’s solid tumour neoantigen T cell receptor research platform and Gaithersburg manufacturing facility for undisclosed amount.
AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for patients with moderate to severe systemic lupus erythematosus.
The FDA have authorised REGEN-COV monoclonal antibody therapy for emergency use as prevention for COVID-19 in certain patients.
This article addresses early planning for paediatric evaluation of certain molecularly targeted oncology drugs, including biological products, for which original New Drug Application (NDAs) and Biological License Application (BLAs) are expected to be submitted to FDA, in accordance with The FDA Reauthorization Act (FDARA).
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.